Erasca, a San Diego, CA-based develper of oncology programs, completed a $200m Series B financing round.
The round, which brought the total capital raised to more than $260m, was co-led by Arch Venture Partners and Cormorant Asset Management with participation from new investors Singapore-based investor EDBI, Invus, Terra Magnum Capital Partners, and existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners.
The company intends to use the funds for the clinical development of multiple oncology programs and further advance its in-house drug discovery pipeline.
Founded in 2018 and led by Jonathan E. Lim, M.D., chairman, CEO and co-founder, Erasca has assembled a stong pipeline of targeted therapies directed at undisclosed targets through in-house drug discovery, as well as active pipeline expansion through collaborations with world-class academic and biopharmaceutical organizations.
FinSMEs
27/04/2020